{"nct_id":"NCT03544281","title":"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","status_verified_date":"2025-02","start_date":"2018-09-20","start_date_type":"ACTUAL","primary_completion_date":"2023-02-28","primary_completion_date_type":"ACTUAL","completion_date":"2024-02-28","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["GSK"]}